Consumer Discretionary · Wholesale-Medical, Dental & Hospital Equipment & Supplies · NYSE · CIK 75252 · FYE Dec 31 · no price history on file
Mkt cap $266M
Price series unavailable — No prices available for ACH in [1900-01-01, 2026-07-29]. This symbol may require bring-your-own-key (BYOK) data.
| Short interest7.3% of sh out |
| Days to cover9.3d |
| 13F net flow (QoQ)−4.35% |
| Top-10 13F concentration67.3% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$2.72B |
| Earnings (TTM)-$1.08B |
| Net margin−39.8% |
| ROIC39.9% |
| Total debt / EBITDA1.03× |
| Sales growth 3Y−34.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
No return windows available for ACH.
No risk analytics available for ACH.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Coliseum Capital Management, LLC | 13.1M | $30M | 17.11% | +0.0% |
| BlackRock, Inc. | 5.2M | $12M | 6.84% | −3.3% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.6M | $8M | 4.75% | −10.4% |
| BANK OF AMERICA CORP /DE/ | 3.4M | $8M | 4.45% | +106.9% |
| Invenomic Capital Management LP | 3.4M | $8M | 4.40% | −3.8% |
| D. E. Shaw & Co., Inc. | 3.3M | $8M | 4.32% | −6.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3M | $7M | 4.29% | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.7M | $6M | 3.46% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.08 | — | $627.8M | −6.8% |
| 2025-12-31 | 2026-02-19 | — | — | $709.0M | — |
| 2025-09-30 | 2025-10-30 | −$1.94 | — | $697.3M | +1.5% |
| 2025-06-30 | 2025-08-11 | −$11.30 | — | $681.9M | +3.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Diabetes Product 28% · Sleep Therapy Product 27% · Home Respiratory Therapy Product 16% · Product And Service Other 10% · Ostomy 8%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
